(Q37788236)

23 August 2017

title

Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma (English)

1 reference

23 August 2017

Bendamustine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma (English)

1 reference

chronic lymphocytic leukemia

11 July 2024

0 references

1 reference

1 reference

1 reference

2

Bruce D Cheson

1 reference

23 August 2017

Chaitra Ujjani

1

1 reference

23 August 2017

language of work or name

1 reference

1 September 2010

1 reference

full work available at URL

23 August 2017

http://www.future-drugs.com/doi/abs/10.1586/era.10.116

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20836669

http://www.tandfonline.com/doi/pdf/10.1586/era.10.116

11 July 2024

1 reference

Expert Review of Anticancer Therapy

11 July 2024

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1353-1365

1 reference

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.116

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

21 January 2018

series ordinal

3

1 reference

Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.

11 July 2024

series ordinal

8

1 reference

11 July 2024

12

90

1357

Bergmann

2005

1 reference

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study

11 July 2024

series ordinal

24

1 reference

11 July 2024

Identifiers

DOI

10.1586/ERA.10.116

1 reference

23 August 2017

1 reference